Market Capitalization

Amid market volatility, the S&P 500 firm reinforces its financial strength with a massive share repurchase program and its 34th year of dividend growth.

With strong growth and a high valuation, BrightSpring's upcoming Investor Day is a key moment to outline its strategy for profitability and market leadership.

USANA posts higher 2025 sales fueled by its Hiya and Rise brands, but a Q4 loss and a shrinking core business reveal the high cost of its transformation.

With a $50.1M financing led by top investors, Coherus solidifies its strategic pivot from biosimilars to a pure-play oncology powerhouse.

Robinhood's RVI fund offers retail investors access to giants like Stripe for $25 a share. Is it a revolution in access or a high-risk gamble?

Ditching passive holding, Lite Strategy generated $600k from Litecoin options to fund buybacks. Is this the new playbook for corporate crypto finance?

An OTC-listed company's $11.7M deal for a Texas power plant highlights a critical trend: the race to secure private energy for the AI revolution.

Nakamoto Inc. acquires Bitcoin Magazine's parent and a key investment firm in an all-stock deal, raising questions about market influence and shareholder value.

At a key conference, DocGo's CEO will navigate financial headwinds while promoting a vision for proactive, tech-enabled healthcare delivery.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

A strategic merger creates a new aerospace and defense giant, but existing shareholders face significant dilution in a deal laden with both promise and risk.

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

After a soft 2025, Graphic Packaging's CEO faces investors. With the stock lagging, all eyes are on whether its green strategy can deliver growth.

A record-breaking drone and air taxi display at the Spring Festival Gala was more than a show; it was a bold statement on China's low-altitude economy.

Acurx Pharmaceuticals preps for pivotal Phase 3 trials for its novel C. diff antibiotic, Ibezapolstat, with global regulatory alignment in place.

A new partnership signals a major shift in the art market, placing scientific conservation at the heart of determining an asset's long-term value.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

Legrand's plan to repurchase 250,000 shares goes beyond pure financials, signaling a strategic investment in its workforce amid a competitive market.

Fermi America's plan to revive nuclear power for AI's energy needs with a massive Texas campus faces past industry failures and new legal scrutiny.

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?